No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Antibody-B (03681.HK) plans to hold a board of directors meeting on August 19 to approve its mid-term performance.
China Antibody-B (03681.HK) announced that the board of directors has scheduled a board meeting on Monday, August 19, 2024 to consider and approve the group's interim performance for the six months ending June 30, 2024, as well as to handle other matters.
Sinomab Bioscience Administers First Dose of Atopic Dermatitis Drug
SinoMab Doses First Patient in Clinical Study of Atopic Dermatitis Drug in China
China Antibody-B (03681): The first patient in the Phase 1b clinical trial in China was treated with SM17.
China Antibody-B (03681) issued a notice on June 5, 2024, regarding the treatment of atopic dermatitis with SM17...
SINOMAB BIO-B: Annual Report 2023
No Data
